Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomised, Double-Blind Placebo-Controlled, First in Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ANPA-0073 in Healthy Volunteers

Next Previous
X
Search
Trial Profile

A Phase 1, Randomised, Double-Blind Placebo-Controlled, First in Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ANPA-0073 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ANPA-0073 (Primary)
  • Indications Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 24 May 2023 Results presented at the 119th International Conference of the American Thoracic Society
    • 18 May 2023 According to a Structure Therapeutics media release, data from this study will be presented as scientific poster at the upcoming 2023 American Thoracic Society (ATS) International Conference taking place May 19-24, 2023.
    • 14 Apr 2022 Accrual to date is 88 participants as per Australian New Zealand Clinical Trials Registry record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top